Metabolic characteristics of cortical malformations causing epilepsy
S. G. Mueller(San Francisco VA Medical Center), Michael W. Weiner(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center), Derek Flenniken(San Francisco VA Medical Center), Peter Vermathen(University Hospital of Bern), Jerome Barakos(Sutter Health), Nathan Cashdollar(San Francisco VA Medical Center), Gerald B. Matson(San Francisco VA Medical Center)
Cited by 37
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
|Alzheimer s & Dementia|2018|690